Latest Generation of Balloon-Expandable Valve, the Edwards Sapien 3 Valve: Less Paravalvular Regurgitation but Higher Transvalvular Pressure Gradients.


Journal

The Thoracic and cardiovascular surgeon
ISSN: 1439-1902
Titre abrégé: Thorac Cardiovasc Surg
Pays: Germany
ID NLM: 7903387

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 25 11 2017
medline: 18 7 2019
entrez: 25 11 2017
Statut: ppublish

Résumé

 The latest generation of balloon-expandable valve, the Edwards Sapien 3 valve (S3V), was designed to reduce paravalvular regurgitation (PVR). We retrospectively compared S3V with Edwards Sapien XT valve (SXTV) with regard to postprocedural transvalvular pressure gradients (PGs).  Analysis of 152 patients receiving SXTV and 125 patients receiving S3V between February 2009 and April 2015 was performed. Transvalvular PGs and the incidence and extent of aortic regurgitation (AR) were compared postprocedurally by echocardiography for each valve size.  Postprocedurally, mean PGs for the 23 mm valves were 10.9 ± 5.3 versus 13.9 ± 5.1 (  S3V shows lower incidence of PVR; however, it is associated with significantly higher postprocedural transvalvular PGs for 23 and 26 mm valve sizes. These data might contribute to the scientific discussion, especially with respect to prosthesis selection in individual patients with small annular dimension.

Sections du résumé

BACKGROUND BACKGROUND
 The latest generation of balloon-expandable valve, the Edwards Sapien 3 valve (S3V), was designed to reduce paravalvular regurgitation (PVR). We retrospectively compared S3V with Edwards Sapien XT valve (SXTV) with regard to postprocedural transvalvular pressure gradients (PGs).
METHODS METHODS
 Analysis of 152 patients receiving SXTV and 125 patients receiving S3V between February 2009 and April 2015 was performed. Transvalvular PGs and the incidence and extent of aortic regurgitation (AR) were compared postprocedurally by echocardiography for each valve size.
RESULTS RESULTS
 Postprocedurally, mean PGs for the 23 mm valves were 10.9 ± 5.3 versus 13.9 ± 5.1 (
CONCLUSION CONCLUSIONS
 S3V shows lower incidence of PVR; however, it is associated with significantly higher postprocedural transvalvular PGs for 23 and 26 mm valve sizes. These data might contribute to the scientific discussion, especially with respect to prosthesis selection in individual patients with small annular dimension.

Identifiants

pubmed: 29172210
doi: 10.1055/s-0037-1608750
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

236-242

Informations de copyright

Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

Disclosure The authors report no conflicts of interest in this work.

Auteurs

Kaveh Eghbalzadeh (K)

Department of Cardiothoracic Surgery, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Elmar W Kuhn (EW)

Department of Cardiothoracic Surgery, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Anton Sabashnikov (A)

Department of Cardiothoracic Surgery, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Carolyn Weber (C)

Department of Cardiothoracic Surgery, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Parwis Baradaran Rahmanian (PB)

Department of Cardiothoracic Surgery, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Florian Siedek (F)

Department of Radiology, Universitätsklinikum Köln, Cologne, Germany.

Victor Mauri (V)

Department of Cardiology, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Tanja Rudolph (T)

Department of Cardiology, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Stephan Baldus (S)

Department of Cardiology, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Navid Madershahian (N)

Department of Cardiothoracic Surgery, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Thorsten C Wahlers (TC)

Department of Cardiothoracic Surgery, Heart Center, Universitätsklinikum Köln, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH